Acumen Pharmaceuticals Expects ALTITUDE-AD Phase II Top Line Results in Late 2026, Advances Alzheimer's Candidates with JCR Partnership.

Acumen Pharmaceuticals expects top line results from the ALTITUDE-AD Phase II study in late 2026, as its partnership with JCR advances next-generation Alzheimer's candidates. CEO Daniel J. O'Connell highlighted steady operational progress and a strategic partnership to expand the portfolio during Q2 2025 earnings call.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported its second quarter 2025 financial results, highlighting steady operational progress and strategic partnerships to expand its portfolio. The company expects topline results from the ALTITUDE-AD Phase 2 study in late 2026, as its collaboration with JCR Pharmaceuticals advances next-generation Alzheimer's candidates.

During the earnings call, CEO Daniel J. O'Connell emphasized the company's strong operational execution and the addition of its Enhanced Brain Delivery (EBDTM) program. The EBDTM program, a collaboration with JCR, aims to augment Acumen's pipeline with innovative science in a fiscally responsible manner. The company expects non-clinical data to support the development of an EBD therapy in early 2026, at which point Acumen has an exclusive right to develop up to two development candidates as part of its partnership with JCR.

Acumen's financial results for the second quarter 2025 showed a decrease in cash, cash equivalents, and marketable securities from $197.9 million as of March 31, 2025, to $166.2 million as of June 30, 2025. The decrease is attributed to funding ongoing operations. The company expects this cash to support current clinical and operational activities into early 2027.

Research and Development (R&D) expenses for the three-month period ended June 30, 2025, were $37.1 million, an increase of $17.6 million compared to the same period in 2024. The increase was primarily due to an increase in manufacturing and materials costs and CRO costs associated with the ALTITUDE-AD clinical trial. General and Administrative (G&A) expenses decreased to $4.6 million from $4.8 million in the same period last year, primarily due to immaterial decreases in insurance and recruiting costs.

Acumen reported a loss from operations of $41.8 million for the three-month period ended June 30, 2025, compared to $24.4 million for the same period in 2024. The increase in loss from operations was due to the increased R&D expenses over the prior year period. The net loss was $41.0 million for the three-month period ended June 30, 2025, compared to $20.5 million for the same period in 2024.

Acumen will host a conference call and live audio webcast today, August 12, 2025, at 8:00 a.m. ET. To participate, investors can register using the provided link and follow the instructions for dial-in numbers and PINs.

References:
[1] https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-reports-second-quarter-2025-financial